Eli Lilly and Company $LLY Stock Holdings Lessened by Bank Hapoalim BM

Bank Hapoalim BM reduced its holdings in Eli Lilly and Company (NYSE:LLY) by 4.4% during the second quarter, HoldingsChannel reports. The institutional investor owned 3,071 shares of the company’s stock after selling 143 shares during the period. Bank Hapoalim BM’s holdings in Eli Lilly and Company were worth $2,394,000 as of its most recent filing with the SEC.

Other large investors also recently modified their holdings of the company. Family CFO Inc acquired a new stake in shares of Eli Lilly and Company in the 2nd quarter worth about $54,000. Duquesne Family Office LLC increased its holdings in shares of Eli Lilly and Company by 52.5% in the 1st quarter. Duquesne Family Office LLC now owns 94,830 shares of the company’s stock worth $78,321,000 after acquiring an additional 32,640 shares during the period. Corient IA LLC acquired a new stake in shares of Eli Lilly and Company in the 1st quarter worth about $570,000. Cutter Capital Management LP acquired a new stake in shares of Eli Lilly and Company in the 1st quarter worth about $14,866,000. Finally, Emerald Advisors LLC increased its holdings in shares of Eli Lilly and Company by 60.8% in the 2nd quarter. Emerald Advisors LLC now owns 1,021 shares of the company’s stock worth $796,000 after acquiring an additional 386 shares during the period. 82.53% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In other Eli Lilly and Company news, EVP Daniel Skovronsky acquired 1,000 shares of the stock in a transaction dated Tuesday, August 12th. The shares were bought at an average price of $634.40 per share, with a total value of $634,400.00. Following the purchase, the executive vice president directly owned 137,660 shares of the company’s stock, valued at approximately $87,331,504. This trade represents a 0.73% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director J Erik Fyrwald acquired 1,565 shares of the stock in a transaction dated Tuesday, August 12th. The stock was acquired at an average cost of $642.33 per share, for a total transaction of $1,005,246.45. Following the purchase, the director directly owned 74,578 shares in the company, valued at approximately $47,903,686.74. The trade was a 2.14% increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last three months, insiders have acquired 4,514 shares of company stock worth $2,894,841. 0.13% of the stock is owned by insiders.

Eli Lilly and Company Stock Performance

Shares of LLY opened at $840.46 on Friday. The firm’s 50 day moving average is $734.60 and its 200-day moving average is $766.47. The stock has a market capitalization of $795.47 billion, a P/E ratio of 54.93, a P/E/G ratio of 1.14 and a beta of 0.47. The company has a debt-to-equity ratio of 1.86, a current ratio of 1.28 and a quick ratio of 1.00. Eli Lilly and Company has a 12-month low of $623.78 and a 12-month high of $937.00.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings data on Thursday, August 7th. The company reported $6.31 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.59 by $0.72. The company had revenue of $15.56 billion for the quarter, compared to analysts’ expectations of $14.40 billion. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The business’s revenue was up 37.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $3.92 EPS. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. Equities research analysts anticipate that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on LLY. Deutsche Bank Aktiengesellschaft dropped their price objective on shares of Eli Lilly and Company from $1,010.00 to $900.00 and set a “buy” rating on the stock in a report on Monday, August 11th. Leerink Partners reaffirmed a “market perform” rating and issued a $715.00 price objective on shares of Eli Lilly and Company in a report on Thursday, August 7th. Hsbc Global Res raised shares of Eli Lilly and Company from a “moderate sell” rating to a “hold” rating in a report on Wednesday, August 27th. DZ Bank raised shares of Eli Lilly and Company from a “hold” rating to a “strong-buy” rating in a research note on Thursday, August 14th. Finally, Daiwa America cut shares of Eli Lilly and Company from a “strong-buy” rating to a “hold” rating in a research note on Sunday, August 17th. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating and ten have issued a Hold rating to the company. Based on data from MarketBeat.com, Eli Lilly and Company presently has a consensus rating of “Moderate Buy” and an average price target of $933.39.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.